trapezoid glp 1 Tirzepatide Injection HomeKit Tirzepatide (TZP) differentially induces internalization

10.1016/j.neuron.2017.09.042 Neuron 42 Llewellyn-SmithI

The bottom line: Our findings suggest that GLP-1RA and SGLT2i (and especially SGLT2i with the lowest number needed to treat (NNT) for nearly all study outcomes) may be the preferred glucose-lowering agents for cardiovascular risk reduction in patients at moderate risk for CVD, building on and consistent with existing RCT evidence in the high-risk population. This report highlights potential preference for GLP-1 drugs as a first-line treatment for Type 2 diabetes related to its cardioprotective effect

Beyond GLP-1 RAs, a growing wave of more potent incretin-based treatments now offers the potential for even better glycaemic control and weight loss benefits

or jaundice/right upper quadrant pain suggesting gallbladder disease

The medication actually validated some of this

[DOI] [PubMed] [Google Scholar] 189.Willette, B.K.A., and Tsvetanova, N.G